Amarin Receives Approval for VAZKEPA to Reduce Cardiovascular Risk
A round of applause for our research site physicians Dr Sam Henein and Dr Michael O’Mahony for their participation in the Amarin REDUCE-IT hypertriglyceridemia study!
We have written a number of articles that we hope will be of interest to you. This includes health guides for various medical conditions; news about drug development and regulatory issues related to Health Canada and the FDA; and other health-related topics. Clicking on the title of a Health Guide will take you to information on that medical condition. Or click on one of the listed topics, such as Industry News or Diabetes. You can also access recent articles by scrolling down the page or clicking an article under ‘Recent Articles’.
A round of applause for our research site physicians Dr Sam Henein and Dr Michael O’Mahony for their participation in the Amarin REDUCE-IT hypertriglyceridemia study!
The Food and Drug Administration (FDA) of the United States of America has recently issued a statement, updating Research Sites, Investigators, and IRBs on how best to deal with the ongoing challenges posed by COVID-19. These guidelines will help ensure the safety of trial participants, compliance with good clinical practice (GCP), and minimizing risks to
Arthritis is a chronic and debilitating disease identified by symptoms such as joint pain, stiffness, swelling and decreased range of motion. The two most common types of arthritis are osteoarthritis (OA) and rheumatoid arthritis (RA). It is estimated that over 4.6 million Canadians suffer from arthritis, and it is a leading cause of disability. A